Crossmark

Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals

Crossref DOI link: https://doi.org/10.1186/s12913-018-3162-2

Published Online: 2018-05-31

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Morrell, Liz http://orcid.org/0000-0001-6382-1795
Wordsworth, Sarah

Schuh, Anna

Middleton, Mark R.

Rees, Sian

Barker, Richard W.
Funding

Funding for this research was provided by:

Cancer Research UK
License Information

Text and Data Mining valid from 2018-05-31
More Information

Article History

Received: 9 August 2017

Accepted: 30 April 2018

First Online: 31 May 2018

Change Date: 28 March 2019

Change Type: Correction

Change Details: .

Ethics approval and consent to participate

: Not applicable – this article does not contain any studies with human participants or animals performed by any of the authors.

: AS has received consulting fees or honoraria from Roche, Gilead, Abbvie, Janssen and Novartis. MRM has received consulting fees from pharmaceutical companies with CDF-funded drugs, including Roche, Merck, Novartis, BMS and GSK, and has conducted clinical trials for which his institution is funded by the pharmaceutical industry. SR has received fees from Takeda for leadership training. RWB is a non-executive director of Celgene Corporation. LM and SW declare that they have no conflict of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.